Sanofi, GSK Make Novartis Look Scrooge-Like on Swine Flu Vaccine Donations

Recommended Sources

About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

The corporate image teams at Sanofi-Aventis and GlaxoSmithKline can pop the champagne for their victory over Novartis on the swine flu vaccine issue.

Sanofi promised 100 million free vaccines for the World Health Organization and GSK promised 50 million. Novartis, by contrast, said it would not give any vaccine for free. Novartis CEO Daniel Vasella was quoted in the FT saying:

If you want to make production sustainable, you have to create financial incentives.

Sanofi CEO Chris Viehbacher all but called Vasella a Scrooge in his comment to Bloomberg:

We all have to play our part. It can’t be only the rich countries having access to the vaccines, in case of a pandemic.

The move also burnishes GSK chief Andrew Witty’s rep as a master of pr. It’s his second piece of good news in the last two weeks. Back on June 12, GSK earned kudos — and a drug endorsement — from German authorities for not hiding any of its studies of depression drug Wellbutrin (buproprion XL).

Tags: Vaccine, Novartis AG, H1N1 Flu, Healthcare, Jim Edwards

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Voice your 2cents

Web Buzz:

Swine flu vaccine should be available by winter peak

South China Morning Post - 31 days 8 hours 23 minutes ago

Hong Kong is likely to have swine flu vaccines available before the winter flu season peaks, after four drug makers submitted bids to supply them. The Society of Hospital Pharmacists of Hong Kong said it had contacted various drug makers and found that four European companies - Sanofi-Aventis, Novartis, AstraZeneca and GlaxoSmithKline - had put...
France orders $1.4B worth of flu shots$

Fierce Pharma - 130 days 18 hours 3 minutes ago

Not to be outdone by its neighbors, France has ordered a whopping 94 million doses of swine flu vaccine. The government plans to spend almost €1 billion on those doses--$1.4 billion--with contracts to homegrown Sanofi-Aventis as well as GlaxoSmithKline and Novartis. And it's counting on two doses per recipient, so the orders will be enough to...
Sale price for Piramal could reach $1.5bn

Financial Times - 290 days 7 hours 49 minutes ago

NEW YORK, Feb 7 - GlaxoSmithKline and Sanofi-Aventis have emerged as bidders for Indian drug company Piramal Healthcare, with the sale price going potentially as high as $1.5bn, a source familiar with the situation said on Friday. The auction is at an early stage, and not likely to be resolved soon, but it is competitive, the source said
Flu could goose Pneumovax sales

Fierce Pharma - 108 days 17 hours 25 minutes ago

We know that antiviral drugmakers Roche and GlaxoSmithKline are reaping big sales from the H1N1 swine flu pandemic. And that vaccine makers--including Glaxo, Sanofi-Aventis, Baxter, and more--are, too. But could the swine flu pandemic be a boost to Merck's pneumonia vaccine? If doctors and patients follow some public health advice, it will....
GSK claims 'rapid progress' on swine flu vaccine

Health Service Journal - 110 days 21 hours 40 minutes ago

Drugs company GlaxoSmithKline says it is making rapid progress on its swine flu vaccine. Total doses ordered by governments worldwide so far total 291 million. The company aims to make the vaccine for the H1N1 swine flu virus available from September onwards with shipping expected in the second half of 2009 and early 2010. Although...